In light of the established role of FcRn in slowing the CL of therapeutic IgG antibodies and in the regulation of circulating albumin homeostasis, we hypothesized that elevated pembrolizumab CL and reduced albumin observed in tumour‐bearing, cachectic mice could be attributed, at least in part, to reduced FcRn expression. This evidence concerns the gene ALB and neoplasm.